James Musser still remembers the first time his team sequenced a particularly aggressive strain of Streptococcus dysgalactiae subspecies equisimilis (SDSE) from a Houston patient with necrotizing myositis—a rare, flesh-destroying infection that moves with terrifying speed. That moment sparked a deeper investigation into a pathogen that’s quietly rising in threat but remains largely under the radar. Now, in a breakthrough study published in The American Journal of Pathology, Musser and his team at Houston Methodist have mapped the genetic machinery that allows SDSE to survive and thrive during severe infections, uncovering key differences from its notorious cousin, Strep A.
While Strep A has long dominated public health conversations, SDSE is emerging as a significant cause of invasive disease, including life-threatening muscle infections and sepsis. Yet, until now, little was known about which genes enable it to cause such damage. Using a powerful genomic tool called transposon-directed insertion-site sequencing (TraDIS), Musser’s team analyzed two closely related SDSE strains—SDSE GGS_124 and SDSE GGS_240—identifying the precise genes essential for survival both in lab cultures and during actual muscle infection in experimental models.
The results were revealing. The study pinpointed 348 core genes critical for SDSE growth under laboratory conditions, narrowing down to 126 genes indispensable during active infection. Among these were genes involved in nutrient uptake, stress response, and immune evasion—functions that allow the bacterium to persist in hostile host environments. Surprisingly, several genes known to enhance virulence in Strep A were found to impair SDSE when active, highlighting fundamental biological differences between the two pathogens despite their close genetic relationship.
"By defining which genes are truly required for growth and survival of the bacteria during infection, this work provides a foundation for understanding how SDSE causes severe disease and provides important information that may help in creating a SDSE vaccine," said Musser, chair of the Department of Pathology and Genomic Medicine and director of the Center for Infectious Diseases at Houston Methodist.
This genetic roadmap is more than an academic achievement—it’s a strategic asset. With invasive SDSE infections on the rise globally and limited treatment options beyond antibiotics, the findings open a clear path toward targeted therapies and, potentially, a much-needed vaccine. The study’s strain-specific insights also underscore the importance of precision in vaccine design, as even small genetic differences can alter infection outcomes.
As SDSE continues to evolve and spread, the Houston team’s work stands as a critical step forward—not just in confronting one bacterium, but in refining how we tackle emerging infectious diseases with genomic precision. The next chapter may well be written in a lab not far from where it all began: Houston.